Restart Life Sciences (NMLSF) Stock Price & Analysis

NMLSF Stock Chart & Stats

$0.01$0.00(7.04%)

At close: Nov 02 9:30 AM EST

Day’s Range: $0.02 - $0.02
52-Week Range: $0.01 - $0.12
Previous Close: $0.01
Volume: N/A
Average Volume (3M): 715
Market Cap: $3.57M
Enterprise Value: $4.75M
Total Cash (Recent Filing): $762.36K
Total Debt (Recent Filing): $348.35K
Price to Earnings (P/E): ―
Beta: 4.04
Next Earnings: Dec 02, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Balance-sheet Recovery

Positive equity in 2025 and modest leverage provide a stronger financial base than the preceding years. This improvement may support financing flexibility and reduce immediate balance-sheet pressure, although the benefit remains tempered by the company’s prior equity instability.

Asset-base Rebuilding

A rebuilt asset base suggests the company retains or has developed resources that could support future operations and strategic execution. This is a constructive foundation over the next several quarters, even though the pack does not show that these assets are yet generating recurring revenue.

Improving Cash-flow Trend

The reduction in cash outflow from the 2021–2022 trough indicates some improvement in cash discipline or operating requirements. If sustained, this could extend funding runway and reduce capital pressure, although cash self-sufficiency has not yet been achieved.

Bears Say

No Recurring Revenue

The absence of recurring revenue leaves the business without a demonstrated commercial engine and makes operating losses difficult to absorb. Until revenue begins to scale consistently, the company’s ability to fund growth internally and establish durable earnings power remains very limited.

Persistent Cash Burn

Repeated negative operating and free cash flow shows that the company is not yet self-funding its operations. Continued cash burn can require external capital, limit investment flexibility, and increase financing risk over the next several quarters unless operating performance improves materially.

Volatile Equity Position

The history of negative equity signals financial instability and can constrain access to financing or increase dependence on capital-raising activity. Although 2025 improved, the recent volatility means balance-sheet resilience has not yet been demonstrated through a sustained operating cycle.

Restart Life Sciences News

Nova Mentis Announces Share Consolidation and Name Change

Nova Mentis Life Science (TSE:NOVA) has released an update. Nova Mentis Life Sciences Corp. is set to undergo a share consolidation, reducing its outstanding shares from 148 million to approximately

2y agoNMLSF HN3Q

Nova Mentis Appoints New CEO to Drive Growth

Nova Mentis Life Science (TSE:NOVA) has released an update. Nova Mentis Life Science Corp. appoints Steve Loutskou as the new President and CEO, aiming to drive future growth with his

2y agoNMLSF HN3Q

Nova Mentis Life Science Announces Strategic IP Deal

Nova Mentis Life Science (TSE:NOVA) has released an update. Nova Mentis Life Science Corp. has announced an agreement to assign its intellectual property related to the mRNA Neuro Panel and

2y agoNMLSF HN3Q

Nova Mentis Welcomes New Board Member

Nova Mentis Life Science Corp (TSE:NOVA) has released an update. Nova Mentis Life Science Corp., a Canadian biotech leader in neuroinflammatory diagnostics and therapeutics, has announced the addition of experienced

2y agoNMLSF HN3Q

NMLSF FAQ

What was Restart Life Sciences’s price range in the past 12 months?

Restart Life Sciences lowest stock price was $0.01 and its highest was $0.12 in the past 12 months.

What is Restart Life Sciences’s market cap?

Restart Life Sciences’s market cap is $3.57M.

When is Restart Life Sciences’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Restart Life Sciences’s earnings last quarter?

Restart Life Sciences released its earnings results on Aug 27, 2026. The company reported -$0.012 earnings per share for the quarter.

Is Restart Life Sciences overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Restart Life Sciences pay dividends?

Restart Life Sciences does not currently pay dividends.

What is Restart Life Sciences’s EPS estimate?

Restart Life Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Restart Life Sciences have?

Restart Life Sciences has 62,506,542 shares outstanding.

What happened to Restart Life Sciences’s price movement after its last earnings report?

Restart Life Sciences reported an EPS of -$0.012 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Restart Life Sciences?

Currently, no hedge funds are holding shares in NMLSF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description